A phase 3 study presented at the 2024 AANEM conference showed that the investigational monoclonal antibody nipocalimab improved outcomes in patients with generalized myasthenia gravis (gMG) over 24 weeks. The drug targets the neonatal fragment crystallizable receptor (FcRn) to reduce autoantibodies in gMG. Results demonstrated a significant improvement in the primary efficacy endpoint, the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, as well as secondary endpoints. While the drug was well tolerated, some side effects were noted. Nipocalimab could potentially become an additional treatment option in the field of MG, particularly for continuous dosing compared to cyclic dosing.
Source link
Sustained Control with New mAb for Myasthenia Gravis
